Article ID Journal Published Year Pages File Type
3281680 Clinical Gastroenterology and Hepatology 2016 41 Pages PDF
Abstract
In a prospective study of patients with chronic GERD, esophageal acid reflux was reduced greatly by LARS or esomeprazole therapy. However, patients receiving LARS had significantly greater reductions in 24-hour esophageal acid exposure after 6 months and 5 years. Esophageal and gastric pH, off and on therapy, did not predict long-term outcomes of patients. Abnormal supine acid exposure predicted esomeprazole dose escalation. ClinicalTrials.Gov identifier: NCT00251927 (available: http://clinicaltrials.gov/ct2/show/NCT00251927).
Related Topics
Health Sciences Medicine and Dentistry Gastroenterology
Authors
, , , , , , , , , , , ,